A view from the Center

>

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Can the world’s biggest companies save health care?

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

It’s no secret that we often don’t get what we pay for when it comes to health care. While we spend upwards of $3.5 trillion a year for health care in the US1, our longevity, infant and child mortality, and maternal mortality fall behind other countries.2 Eric Topol, author of the book Deep Medicine,

Read more

The Future of Health: You need to believe it to see it

by Neal Batra, Principal, Deloitte Consulting LLP

Over the past several months, my colleagues and I have been detailing Deloitte’s vision for the future of health to our health and life sciences clients. In meetings and presentations, we describe a landscape that looks vastly different from what we have today. Some of our clients are understandably skeptical—especially considering some of the dramatic changes we anticipate.

Read more

The future of health could be ‘udderly’ amazing

by Steve Davis, Deloitte Center for Health Solutions

When it comes to the future of health, it seems that cows (yes, cows!) might be a couple hoof-steps ahead of people. While visiting relatives in Ireland last month, we stopped at a small dairy farm about 90 miles outside of Belfast. What I saw in the barn that afternoon lines up surprisingly well with Deloitte’s vision for the future of health where always-on sensors detect potential health problems long before symptoms surface.

Read more

With drug rebates on the chopping block, stakeholders should prepare for change

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

Early this year, the US Department of Health and Human Services (HHS) proposed eliminating safe-harbor protections for the rebates drug manufacturers pay to pharmacy benefit managers (PBMs), Medicare Part D plans, and Medicaid managed care organizations. At the same time, HHS proposed two new safe-harbor protections for some point-of-sale (POS) price reductions on prescription drugs and certain PBM service fees.

Read more

Digital tech and strong patient-advocacy partnerships could be a win-win-win for pharma, advocacy groups, and patients

by Jonathan Fox, Specialist leader, Deloitte Consulting LLP

I’m in Philadelphia this week for the annual EyeForPharma conference where I’ll be moderating a panel looking into how pharmaceutical companies and advocacy groups can take their relationship to the next level. Both sides have something to gain, and the patient could be the biggest winner.

Pharmaceutical companies often collaborate with patient advocacy groups,

Read more

FDA workshop on achieving medical device safety and cybersecurity: Why trustworthiness, transparency, and resilience are critical

by Steven Darroch, Senior Manager, and Nick Sikorski, Manager, Deloitte & Touche LLP, Deloitte & Touche LLP

An ever-expanding list of medical devices are able to generate, collect, analyze, and transmit data, creating the Internet of Medical Things (IoMT)—a connected infrastructure of health systems and services. As connected devices have become more common, the ability to protect digital information has become essential. Manufacturers that have a solid risk-management strategy could gain a competitive advantage.

Read more